688506.SS in “China Becomes Pharma's Global R&D Engine”
Sichuan Biokin Pharmaceutical Co.,Ltd.
Biokin demonstrated the value of Chinese ADC innovation through Bristol Myers Squibb's multibillion-dollar licensing agreement for the bispecific ADC izalontamab brengitecan.
688506.SS impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to 688506.SS’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 688506.SS impact map…
Price history, marked with story events
Aug 27, 2025 – Aug 28, 2026 · 244 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — Biokin demonstrated the value of Chinese ADC innovation through Bristol Myers Squibb's multibillion-dollar licensing agreement for the bispecific ADC izalontamab brengitecan.
Read the full China Becomes Pharma's Global R&D Engine story